Page 1148 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1114 Part NiNe Transplantation

52. Keown P, Balshaw R, Khorasheh S, et al. Meta-analysis of basiliximab for and hematopoietic stem cell transplantation. Sci Transl Med
immunoprophylaxis in renal transplantation. Biodrugs 2003;17(4):271–9. 2012;4(124):124ra128.
53. Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte 66. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-term follow-up of
globulin and basiliximab induction. N Engl J Med 2008;359(16):1736–8. recipients of combined human leukocyte antigen-matched bone marrow
54. McKeage K, McCormack PL. Basiliximab: a review of its use as induction and kidney transplantation for multiple myeloma with end-stage renal
therapy in renal transplantation. Biodrugs 2010;24(1):55–76. disease. Transplantation 2011;91(6):672–6.
55. Carvalho-Gaspar M, Jones ND, Luo S, et al. Location and time-dependent 67. Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of
control of rejection by regulatory T cells culminates in a failure to combined HLA-mismatched kidney and bone marrow transplantation
generate memory T cells. J Immunol 2008;180(10):6640–8. without maintenance immunosuppression. Am J Transplant
56. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant 2014;14(7):1599–611.
arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 68. Tan J, Wu W, Xu X, et al. Induction therapy with autologous
2010;16(7):809–13. mesenchymal stem cells in living-related kidney transplants: a
57. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of randomized controlled trial. JAMA 2012;307(11):1169–77.
foreign cells. Nature 1953;172(4379):603–6. 69. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting Edge:
58. Ashton-Chess J, Giral M, Brouard S, et al. Spontaneous operational immunological consequences and trafficking of human regulatory
tolerance after immunosuppressive drug withdrawal in clinical renal macrophages administered to renal transplant recipients. J Immunol
allotransplantation. Transplantation 2007;84(10):1215–19. 2011;187(5):2072–8.
59. Orlando G, Soker S, Wood K. Operational tolerance after liver 70. Juvet SC, Whatcott A, Bushell AR, et al. Harnessing regulatory T cells for
transplantation. J Hepatol 2009;50(6):1247–57. clinical use in transplantation: the end of the beginning. Am J Transplant
60. Tzakis AG, Reyes J, Zeevi A, et al. Early tolerance in pediatric liver 2014;14(4):750–63.
allograft recipients. J Pediatr Surg 1994;29(6):754–6. 71. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human
61. Mazariegos GV, Sindhi R, Thomson AW, et al. Clinical tolerance following regulatory T-cells from patients with type 1 diabetes. Diabetes
liver transplantation: long term results and future prospects. Transpl 2009;58(3):652–62.
Immunol 2007;17(2):114–19. 72. Raimondi G, Sumpter TL, Matta BM, et al. Mammalian target of
62. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose rapamycin inhibition and alloantigen-specific regulatory T cells synergize
cyclosporine monotherapy in 31 cadaveric renal allograft recipients. to promote long-term graft survival in immunocompetent recipients.
Transplantation 1999;68(10):1613–16. J Immunol 2010;184(2):624–36.
63. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic 73. DuPage M, Bluestone JA. Harnessing the plasticity of CD4+ T cells
immunosuppression for organ transplantation. Lancet to treat immune-mediated disease. Nat Rev Immunol 2016;16(3):
2003;361(9368):1502–10. 149–63.
64. Orlando G, Hematti P, Stratta RJ, et al. Clinical operational tolerance after 74. Trzonkowski P, Bachetta R, Battaglia M, et al. Hurdles in therapy with
renal transplantation: current status and future challenges. Ann Surg regulatory T cells. Sci Transl Med 2016;7(304):1–18.
2010;252(6):915–28. 75. Banham GD, Clatworthy MR. B-cell biomarkers in transplantation
65. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without – from genes to therapy. Tissue Antigens 2016;85(2):82–92.
GVHD or engraftment syndrome in HLA-mismatched combined kidney 76. Poste G. Bring on the biomarkers. Nature 2011;469(7329):156–7.